Fig. 1

The SOX2OT expression and effects of SOX2OT in glioma. a The expression of SOX2OT in normal brain tissues (NBTs) and glioma tissues of different grades. Data are presented as the mean ± SD (NBTs (n = 5), Grade I(n = 5),Grade II(n = 5), Grade III (n = 8), Grade IV (n = 8)). ^** P < 0.01 vs. NBTs group; ^## P < 0.01 vs. Grade I group; ^△△ P < 0.01 vs. Grade II group; ^ΨΨ P < 0.01 vs. Grade III group. b The expression of SOX2OT in human astrocytes (HA), glioblastoma cell lines (U87 and U251) and glioblastoma stem cells (GSC-U87, GSC-U251). Data are presented as the mean ± SD (n = 5, each group). ^** P < 0.01 vs. HA group; ^## P < 0.01 vs. U87 group; ^ΨΨ P < 0.01 vs. U251 group. c The expression of SOX2OT after cells transfection with sh-SOX2OT plasmids. d CCK-8 assay was used to measure the effect of SOX2OT on the proliferation of GSC-U87 and GSC-U251. e The apoptotic percentages of GSC-U87 and GSC-U251 were detected after SOX2OT knockdown. f Transwell assays were used to measure the effect of SOX2OT on cell migration and invasion of GSC-U87 and GSC-U251. Data represent as the mean ± SD (n = 5,each group). ^** P < 0.01 vs. sh-NC group. Scale bars represent 40 μm